Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01169636
First received: July 22, 2010
Last updated: March 21, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)